Kronos Bio (KRON) ($45MM market cap) was traditionally targeted on most cancers and autoimmune illness therapies, late final yr, the corporate discontinued growth of their lead asset, istisociclib, attributable to issues of safety and introduced a plan to discover strategic options. On the time, I used to be nervous about their massive working lease obligation and ended up passing on including it to my busted biotech basket as there was no scarcity of cleaner alternatives on the time.
On Might 1st, Kevin Tang’s liquidation automobile, Concentra Biosciences, entered into an settlement to purchase KRON for $0.57/share in money plus a CVR, the CVR is structured in another way than lots of Tang’s current offers the place the CVR is usually simply IP inclinations, right here the CVR consists of a collection of potential payouts:
(i) 50% of the online proceeds within the case of a disposition of the Firm’s product candidates generally known as KB-9558 and KB-7898 that happens inside 2 years following closing; (ii) 100% of the online proceeds within the case of a disposition of the Firm’s product candidates generally known as KB-0742, lanraplenib and entospletinib that happens previous to closing; (iii) 100% of price financial savings realized previous to closing; (iv) 80% of price financial savings realized between the merger deadline and the second (2nd) anniversary of the merger deadline; and (v) 50% of price financial savings realized between the second (2nd) anniversary of the merger deadline and the third (3rd) anniversary of the merger deadline, every pursuant to the contingent worth rights settlement (the “CVR Settlement”).
Payouts (i) and (ii) are exhausting to foretell and certain of minimal worth, the legacy IP property in (ii) should be offered (however not closed) previous to the merger closing and (i) is their pre-clinical property, who is aware of how a lot these are value however the two yr clock is fairly gameable, any worth there probably accrues to Tang.
Payouts (iv) and (v) relate primarily to price financial savings, subleasing or an early exit to their working lease for a 40+okay sq ft facility situated in Cambridge, MA. The lease ends in February 2031 and it has roughly $30MM remaining, given the lengthy timeframe, Tang might potential recreation this one by again weighting any lease modification/termination to present him the perfect payout and keep away from paying CVR holders.
Payout (iii) is the place the potential money is for CVR holders, it is going to be paid no later than 60 days following the merger closing, the financial savings calculation is as follows:
“Extra Closing Web Money Proceeds” means 100% of the quantity by which the Closing Web Money as lastly decided pursuant to Part 2.01(d) of the Merger Settlement exceeds $40,000,000, adjusted for any claims that come up previous to 30 days following the Merger Closing Date that aren’t accounted for in such Closing Web Money.
“Closing Web Money” means, with out duplication, (i) the Firm’s money and money equivalents, restricted money, and investments as of the Money Willpower Time, decided in accordance with GAAP, utilized on a foundation in line with the Firm’s utility thereof within the Firm’s consolidated monetary statements, minus (ii) Indebtedness of the Firm as of the Money Willpower Time, minus (iii) the Transaction Bills, minus (iv) the Estimated Prices Put up-Merger Closing, minus (v) $400,000 for the CVR Expense Cap underneath the CVR Settlement.
The curious a part of this transaction is the $40MM threshold, why is it so low when the NCAV as of three/31/25 is $73.5MM? CVRs are supposed to bridge the hole between consumers and sellers on how a lot an asset is value, right here the asset is primarily money which ought to have minimal uncertainty given the short merger shut (a young supply is required to be launched by 5/15/25). What would Tang be defending himself in opposition to with such a low closing money quantity? Istisociclib did have issues of safety, however no authorized proceedings have been disclosed that meet a reporting threshold.
Beneath is my try at a again of the envelope calculation of the Extra Closing Web Money Proceeds worth, shares commerce for $0.72/share at present, implying a $0.15/CVR worth:
The “Estimated Prices Put up-Merger Closing” is the place some potential video games could possibly be performed:
“Estimated Prices Put up-Merger Closing” means all prices that the Surviving Company would incur post-Merger Closing, together with prices related to: (i) CMC Actions; (ii) scientific actions; (iii) remaining lease-related obligations (together with lease, frequent space upkeep, property taxes and insurance coverage); and (iv) an combination of $250,000 for any authorized Proceedings and settlements.
Whereas the event pipeline is paused, probably an argument could possibly be made that spending some cash to advance KB-9558 and KB-7898 could possibly be worthwhile to CVR holders as they’d receives a commission 50% of any disposition proceeds? I do not see it, however does not imply administration won’t have an settlement with Tang to incorporate some spend in that bucket. Within the newest 10-Q, all their R&D prices gave the impression of legacy bills, not ongoing bills:
Analysis and growth bills had been $2.1 million for the three months ended March 31, 2025, in comparison with $14.2 million for the three months ended March 31, 2024. The lower of $12.1 million was primarily attributable to a $6.0 million discount in consulting and different exterior analysis bills, a $4.2 million lower in personnel-related prices and a $1.9 million lower in amenities, depreciation and different prices. These decreases had been primarily associated to the discontinuation of the istisociclib scientific trial in November 2024, diminished headcount in our analysis and growth group following the restructuring actions and reclassification of lease prices to basic and administrative bills. Analysis and growth bills for the three months ended March 31, 2025 had been associated to efficiency obligations underneath the Transition Settlement and continued wind down of analysis and growth actions.
I kind of anticipate to be screwed right here, simply not fairly positive how, however the alternative for a fast buck is just too tempting, I added a small place.
Disclosure: I personal shares of KRON